Affordable Access

Tacrolimus- and sirolimus-induced human beta cell dysfunction is reversible and preventable

Authors
  • Dai, Chunhua
  • Walker, John T.
  • Shostak, Alena
  • Padgett, Ana
  • Spears, Erick
  • Wisniewski, Scott
  • Poffenberger, Greg
  • Aramandla, Radhika
  • Dean, E Danielle.
  • Prasad, Nripesh
  • Levy, Shawn E.
  • Greiner, Dale L.
  • Shultz, Leonard D.
  • Bottino, Rita
  • Powers, Alvin C.
Publication Date
Jan 16, 2020
Source
[email protected]
Keywords
License
Unknown
External links

Abstract

Posttransplantation diabetes mellitus (PTDM) is a common and significant complication related to immunosuppressive agents required to prevent organ or cell transplant rejection. To elucidate the effects of 2 commonly used agents, the calcineurin inhibitor tacrolimus (TAC) and the mTOR inhibitor sirolimus (SIR), on islet function and test whether these effects could be reversed or prevented, we investigated human islets transplanted into immunodeficient mice treated with TAC or SIR at clinically relevant levels. Both TAC and SIR impaired insulin secretion in fasted and/or stimulated conditions. Treatment with TAC or SIR increased amyloid deposition and islet macrophages, disrupted insulin granule formation, and induced broad transcriptional dysregulation related to peptide processing, ion/calcium flux, and the extracellular matrix; however, it did not affect regulation of beta cell mass. Interestingly, these beta cell abnormalities reversed after withdrawal of drug treatment. Furthermore, cotreatment with a GLP-1 receptor agonist completely prevented TAC-induced beta cell dysfunction and partially prevented SIR-induced beta cell dysfunction. These results highlight the importance of both calcineurin and mTOR signaling in normal human beta cell function in vivo and suggest that modulation of these pathways may prevent or ameliorate PTDM.

Report this publication

Statistics

Seen <100 times